Highlights

  • RMD shares closed at $31.96, up 0.06% on 24 August 2026
  • Fourth-quarter and FY2026 results recently reported
  • Latest investor presentation released on 6 August, following the FY2026 earnings announcement
  • Continued focus on sleep-apnoea treatment, respiratory care and digital-health technologies

ResMed Inc (ASX:RMD) shares closed at $31.96, largely unchanged with a 0.06% gain on 24 August 2026. The stock remains on investor radars as the company continues to build out its connected healthcare ecosystem alongside its core sleep-apnoea and respiratory-care device business.

About ResMed Inc

ResMed Inc is a global leader in sleep-apnoea treatment, respiratory care and digital-health technologies, with a dual listing that includes the ASX. The company designs and manufactures medical devices used to treat sleep-disordered breathing, chronic obstructive pulmonary disease and other respiratory conditions, serving patients across both home-care and clinical settings worldwide. Beyond its core hardware business, ResMed has increasingly focused on building out a connected healthcare ecosystem, integrating its devices with software and data platforms that allow clinicians and patients to monitor treatment adherence and outcomes remotely. This shift toward connected, software-enabled care reflects a broader industry trend toward value-based healthcare, where ongoing patient engagement and data-driven insights are seen as key differentiators. ResMed's global scale, extensive patient base and long history of innovation in respiratory medicine have positioned it as one of the most significant companies in the global sleep and respiratory-care device market, with continued growth expected as awareness and diagnosis rates for sleep apnoea rise internationally.

Key Developments

ResMed recently reported its fourth-quarter and FY2026 results, with management continuing to focus on expanding its connected healthcare ecosystem as a central pillar of the company's long-term strategy. The company's latest investor presentation was released on 6 August, following the FY2026 earnings announcement, providing further detail on the drivers behind the reported results and management's priorities for the year ahead. ResMed remains focused on its core areas of sleep-apnoea treatment, respiratory care and digital-health technologies, with connected devices and software increasingly important to its overall strategy as the company seeks to differentiate itself through data-driven patient engagement tools. Investors are watching product innovation, Market Share and the company's ability to grow its global patient base, all of which are seen as key indicators of ResMed's ability to sustain its Long-term Growth trajectory. The company's ongoing Investment in Research and Development remains an important driver of future product launches and growth, supporting a pipeline of new devices and software features designed to enhance both clinical outcomes and patient adherence to therapy over time.

Conclusion

ResMed's continued focus on expanding its connected healthcare ecosystem, alongside its core respiratory-care and sleep-apnoea treatment businesses, reflects a company positioning itself at the intersection of medical devices and digital health. With ongoing investment in research and development supporting future product launches, ResMed appears well placed to capture continued global Demand growth. Investors will continue to watch product innovation and patient-base expansion as key markers of the company's progress in the periods ahead.